<DOC>
	<DOCNO>NCT02175615</DOCNO>
	<brief_summary>The specific objective study : Primary : 1 ) To determine relationship cyclosporine AUC achieve prior engraftment severe aGVHD ( grade III IV ) Secondary : 1 . To determine relationship individual concentration-time point achieve prior engraftment severe aGVHD ( grade III IV ) 2 . To validate previously develop LSS determine cyclosporine AUC IV administration steady state 3 . To describe relationship cyclosporine AUC individual concentration-time point achieve prior engraftment HSCT outcome ( clinically significant aGVHD ( grade II IV ) , hypertension , engraftment failure , relapse</brief_summary>
	<brief_title>Pharmacological Predictors Successful Cyclosporine Acute GVHD Prophylaxis Children Undergoing HSCT</brief_title>
	<detailed_description />
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>less 18 year age undergoing allogeneic myeloablative HSCT one participate centre schedule receive cyclosporine aGVHD prophylaxis minimum patient weight : 6.4kg &lt; 6 month old 7.2kg &gt; 6 month old All patient guardian provide informed consent assent appropriate . Initial contact make member patient 's current care team . Consent obtain coinvestigator CTSU personnel . receipt voriconazole posaconazole within 14 day first cyclosporine dose time engraftment</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>CYCLOSPORINE</keyword>
	<keyword>ACUTE GRAFT VERSUS HOST DISEASE</keyword>
	<keyword>PROPHYLAXIS</keyword>
	<keyword>CHILDREN</keyword>
	<keyword>HAEMATOPOIETIC STEM CELL TRANSPLANT</keyword>
</DOC>